Pharmaceutical Technology on MSN
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback